122745-41-9Relevant academic research and scientific papers
Synthesis of N-(tert-Butyloxycarbonyl)-CBI, CBI, CBI-CDPI1, and CBI-CDPI2: Enhanced Functional Analogues of CC-1065 Incorporating the 1,2,9,9a-Tetrahydrocyclopropabenzindol-4-one (CBI) Left-Hand Subunit
Boger, Dale L.,Ishizaki, Takayoshi,Kitos, Paul A.,Suntornwat, Oranart
, p. 5823 - 5832 (1990)
Full details of the synthesis of N-(tert-butyloxycarbonyl)-1,2,9,9a-tetrahydrocyclopropabenzindol-4-one constituting a more stable functional analogue of the CC-1065 left-hand subunit are described.The resolution of an immediate CBI
Synthesis, biological evaluation, and live cell imaging of novel fluorescent duocarmycin analogs
Tietze, Lutz F.,Behrendt, Frank,Pestel, Galina F.,Schuberth, Ingrid,Mitkovski, Mi?o
, p. 2559 - 2570 (2012)
For a better understanding of the mode of action of duocarmycin and its analogs, the novel fluorescent duocarmycin derivatives 13-15 and 17b-19b were synthesized, and their bioactivity as well as their cellular uptake investigated using confocal laser sca
Bifunctional cytotoxin and application thereof
-
Paragraph 0037-0038, (2020/03/11)
The invention provides a bifunctional cytotoxin containing a duocarmycin analogue and a nitrogen mustard compound, and further provides an antibody drug conjugate coupled with the bifunctional cytotoxin and pharmaceutical application of the antibody drug
METHOD FOR THE SYNTHESIS OF MONOPROTECTED BIFUNCTIONAL PRODRUGS AND ANTIBODY DRUG CONJUGATES BASED THEREON AS WELL AS A METHOD FOR PREPARING ANTIBODY DRUG CONJUGATESMETHOD FOR THE SYNTHESIS OF MONOPROTECTED BIFUNCTIONAL PRODRUGS AND ANTIBODY DRUG CONJUGATES BASED THEREON AS WELL AS A METHOD FOR PREPARING ANTIBODY DRUG CONJUGATES
-
Page/Page column 23, (2019/02/25)
The present invention relates to a method for the synthesis of compounds useful in the preparation of antibody drug conjugates (ADC), namely, monoprotected dimeric bifunctional prodrugs based on duocarmycin analogs. In a further aspect, compounds obtained by the method according to the present invention are provided. The monoprotected bifunctional prodrug is used for preparing antibody drug conjugates composed of an antibody moiety and the monoprotected bifunctional prodrug. The antibody compound conjugates thus obtained are provided. Further, a method of preparing an antibody drug conjugate composed of two identical or two different antibody moieties is provided as well as the antibody compound conjugate containing two different antibody moieties accordingly. These conjugates can be used in pharmaceutical compositions, in particular, for use in treatment of tumors, e.g. for use in ADC therapy.
Bifunctional cytotoxic agents
-
Page/Page column 65, (2018/11/02)
Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.
ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS
-
, (2018/04/27)
Provided herein are isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers, antibody-drug conjugates comprising them and methods of use for killing cells and treating disease.
ASYMMETRIC CONJUGATE COMPOUNDS
-
Page/Page column 168, (2017/12/01)
The invention relates to compound of formula (I): A-X1-L-X2-B and salts, solvates and tautomers thereof, which are useful as medicaments, in particular as anti-proliferative agents and for use as a drug in an antibody-drug conjugate;
SACCHARIDE DERIVATIVE OF A TOXIC PAYLOAD AND ANTIBODY CONJUGATES THEREOF
-
Page/Page column 139, (2016/01/25)
A molecule comprising a saccharide bound via an O- glycosidic bond to a hydroxyl group of a toxic payload molecule is disclosed. An antibody-drug conjugate comprising an antibody covalently bound to a toxic payload molecule, optionally via a linker group,
SELF-IMMOLATIVE LINKERS CONTAINING MANDELIC ACID DERIVATIVES, DRUG-LIGAND CONJUGATES FOR TARGETED THERAPIES AND USES THEREOF
-
, (2015/03/28)
The invention provides a therapeutic drug and targeting conjugate, pharmaceutical compositions containing these conjugates in pharmaceutical composition, and uses of these conjugates in anti-neoplastic and other therapeutic regimens. Also provided are novel intermediates thereof. The conjugates provide a therapeutic drug fragment or prodrug fragment bound to a targeting moiety via a linker which comprises a substrate cleavable by a protease such as Cathepsin B. The targeting moiety is a ligand which targets a cell surface molecule, such as a cell surface receptor on an anti-neoplastic cell. The ligand may function solely as a targeting moiety or may itself have a therapeutic effect. Following administration of the therapeutic drug and targeting conjugate of formula I and exposure of the conjugate to the protease specific for the substrate, the linker is cleaved and the targeting moiety is separated from the conjugate, which causes the drug fragment or prodrug fragment to convert to the drug or prodrug. The recited conjugates are useful in anti-neoplastic therapies. Also provided are methods of making the therapeutic drug and targeting conjugates and intermediates thereof, and kits comprising the therapeutic drug and targeting conjugates.
Asymmetric synthesis of 1,2,9,9a-tetrahydrocyclopropa[ c ]benzo[ e ]indol-4-one (CBI)
Lajiness, James P.,Boger, Dale L.
, p. 583 - 587 (2011/03/19)
A short, asymmetric synthesis of the 1,2,9,9a-tetrahydrocyclopropa[c] benzo[e]indol-4-one (CBI) analogue of the CC-1065 and duocarmycin DNA alkylation subunits is described. Treatment of iodo-epoxide 5, prepared by late-stage alkylation of 4 with (S)-glyc
